I think CYDY could get this license deal like this all day long. Probably several similar offers have been put on the table over the years. Notice how JNCE's price is back down, now $4.5 right, closed yesterday at 4.1 So only up 10% since after partnership announcement; basically gave everything away for 180M regulatory milestone payments + low percent of sales. Very bad deal in my opinion if CYDY took this. I would rather they take their chances going alone. We also see issues breaking up the license for just one indication. Probably why no partnership has ever been announced for leronlimab, both sides too far. Their best bet imo is to limp along until they get the BLA submitted, get mono pivotal started, finally start the mTNBC trial, work on licensing the prostate cancer test or these other deals besides leronliimab, like the Chinese company.

Quote:

---

The License Agreement provides Celgene with the sole right, at its sole cost and expense, to develop, seek regulatory approval for, manufacture and commercialize the Licensed Compounds and any product that comprises a Licensed Compound (each a “Licensed Product”) for all uses and purposes. Celgene is obligated to use commercially reasonable efforts to develop, seek regulatory approval for and commercialize at least one Licensed Product comprising or incorporating the Initial Licensed Compound (any such Licensed Product, an “Initial Licensed Product”). During the term of the license, the Company is prohibited from developing, manufacturing or commercializing any product, other than Licensed Products, that contains an antibody or other biologic that is specifically directed to LILRB2 or any related antibody or related biologic.

Pursuant to the terms of the License Agreement, Celgene is required to make a one-time, upfront payment of $50.0 million to the Company. The Company is also entitled to receive payments from Celgene upon the achievement of specified clinical, regulatory and sales milestones by the first Initial Licensed Product to achieve such milestones, including potential clinical and regulatory milestone payments up to an aggregate total of $180.0 million and potential sales milestone payments up to an aggregate total of $300.0 million.

Celgene also agreed to pay the Company royalties at percentage rates ranging from mid-single-digits to low-double-digits, based on future annual net sales of the Initial Licensed Products,

---